[en] In some patients, psoriasis appears refractory to many treatments, particularly when the disease is confined to some specific body regions. In this respect, palmoplantar psoriasis and palmoplantar pustulosis are possibly related conditions in their immunopathomechanisms involving Il-12, IL-23, and Th17. Nail psoriasis and scalp psoriasis are two other particular psoriasis manifestations. Accordingly, ustekinumab was tested in a few of these patients. The present paper is limited to peer-reviewed case reports. Data were not supported by bioinstrumental assessments and controlled trials. Overall, they are indicative of potential efficacy. The cost-effectiveness and the risk-benefit assessments merit further investigations.
PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Lesuisse, Marianne
Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Language :
English
Title :
Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease.
Piérard G. E., Piérard-Franchimont C., Szepetiuk G., Paquet P., Quatresooz P., The therapeutic potential of TNF- α antagonists for skin psoriasis comorbidities. Expert Opinion on Biological Therapy 2010 10 8 1197 1208 2-s2.0-77954665047 10.1517/14712598.2010.500283
Kragballe K., Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails. Current Problems in Dermatology 2009 38 160 171 2-s2.0-70350501147 10.1159/000232309
McGonagle D., Palmou Fontana N., Tan A. L., Benjamin M., Nailing down the genetic and immunological basis for psoriatic disease. Dermatology 2010 221 supplement 1 S15 S22 2-s2.0-77956041854 10.1159/000316171
Griffiths C. E. M., Comparing biological therapies in psoriasis: implications for clinical practice. Journal of the European Academy of Dermatology and Venereology 2010 24 supplement 6 S10 S14 2-s2.0-77956511578 10.1111/j.1468-3083.2010.03831.x
Prinz J. C., From bench to bedsidetranslational research in psoriasis. Journal of the European Academy of Dermatology and Venereology 2010 24 supplement 6 S1 S4 2-s2.0-77956498691 10.1111/j.1468-3083.2010.03829.x
Quatresooz P., Hermanns-Lê T., Piérard G. E., Humbert P., Delvenne P., Piérard-Franchimont C., Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis. A primer. Journal of Biomedicine and Biotechnology 2012 2012 5 147413 10.1155/2012/147413
Di Cesare A., Di Meglio P., Nestle F. O., The IL-23Th17 axis in the immunopathogenesis of psoriasis. Journal of Investigative Dermatology 2009 129 6 1339 1350 2-s2.0-67349230808 10.1038/jid.2009.59
Witowski J., Ksiazek K., Jörres A., Interleukin-17: a mediator of inflammatory responses. Cellular and Molecular Life Sciences 2004 61 5 567 579 2-s2.0-1642369092 10.1007/s00018-003-3228-z (Pubitemid 38372911)
Watanabe H., Kawaguchi M., Fujishima S., Ogura M., Matsukura S., Takeuchi H., Ohba M., Sueki H., Kokubu F., Hizawa N., Adachi M., Huang S. K., Iijima M., Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. Journal of Investigative Dermatology 2009 129 3 650 656 2-s2.0-59949086806 10.1038/jid.2008.294
Pelletier M., Maggi L., Micheletti A., Lazzeri E., Tamassia N., Costantini C., Cosmi L., Lunardi C., Annunziato F., Romagnani S., Cassatella M. A., Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010 115 2 335 343 2-s2.0-75649148842 10.1182/blood-2009-04-216085
Roussel L., Houle F., Chan C., Yao Y., Bérubé J., Olivenstein R., Martin J. G., Huot J., Hamid Q., Ferri L., Rousseau S., IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. Journal of Immunology 2010 184 8 4531 4537 2-s2.0-77952758245 10.4049/jimmunol.0903162
Leonardi C. L., Kimball A. B., Papp K. A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L. T., Gordon K. B., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet 2008 371 9625 1665 1674 2-s2.0-43449111187 10.1016/S0140-6736(08) 60725-4 (Pubitemid 351671883)
Daudén E., Santiago-Et-Sánchez-Mateos D., Sotomayor-López E., García-Díez A., Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. British Journal of Dermatology 2010 163 6 1346 1347 2-s2.0-78649674113 10.1111/j.1365-2133.2010.09995.x
Pettey A. A., Balkrishnan R., Rapp S. R., Fleischer A. B., Feldman S. R., Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. Journal of the American Academy of Dermatology 2003 49 2 271 275 2-s2.0-0042634114 10.1067/S0190-9622(03)01479-8 (Pubitemid 36951276)
Marsland A. M., Chalmers R. J., Hollis S., Leonardi-Bee J., Griffiths C. E., Interventions for chronic palmoplantar pustulosis. Cochrane Database of Systematic Reviews 2006 1 CD001433 2-s2.0-33645502889
Livideanu C. B., Lahfa M., Mazereeuw-Hautier J., Paul C., Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology 2010 221 4 321 323 2-s2.0-78650966609 10.1159/000320961
Gerdes S., Franke J., Domm S., Mrowietz U., Ustekinumab in the treatment of palmoplantar pustulosis. British Journal of Dermatology 2010 163 5 1116 1118 2-s2.0-78249281659 10.1111/j.1365-2133.2010.09897.x
Nuno-Gonzalez A., Gomez de la Fuente E., Vicente-Martin F. J., Lopez-Estebaranz J. L., Good response of hyperkeratotic palmoplantar psoriasis to ustekinumab. Actas Dermosifiliografia 2012 103 169 170
de Unamuno-Bustos B., Balester-Sanchez R., Oliver-Martinez V., Alegre de Miquel V., Ustekinumab for the treatment of palmar-plantar pustulosis. Actas Dermosifiliografia 2011 102 833 835
Au S. C., Goldminz A. M., Kim N., Dumont N., Michelon M., Volf E., Hession M., Luzzul P. F., Andrews I., Kerensky T., Wang A., Yaniv S., Gottlieb A. B., Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe palmoplantar psoriasis. Journal of Dermatological Treatment. In press
Safa G., Martin A., Darrieux L., Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis. Journal of Clinical Rheumatology 2011 17 385 386
Kyriakou A., Patsatsi A., Sotiriadis D., Detailed analysis of specific nail psoriasis features and their correlations with clinical parameters: a cross-sectional study. Dermatology 2011 223 222 229
Grover C., Reddy B. S., Uma C. K., Diagnosis of nail psoriasis: importance of biopsy and histopathology. British Journal of Dermatology 2005 153 6 1153 1158 2-s2.0-28844458383 10.1111/j.1365-2133.2005.06862.x (Pubitemid 41779570)
Jiaravuthisan M. M., Sasseville D., Vender R. B., Murphy F., Muhn C. Y., Psoriasis of the nail: anatomy, pathology, clinicalpresentation, and a review of the literature on therapy. Journal of the American Academy of Dermatology 2007 57 1 1 27 2-s2.0-34250204897 10.1016/j.jaad.2005.07.073 (Pubitemid 46899261)
Augustin M., Ogilvie A., Methods of outcomes measurement in nail psoriasis. Dermatology 2010 221 supplement 1 23 28 2-s2.0-77956023910 10.1159/000316177
Langley R. G., Daudén E., Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010 221 supplement 1 29 42 2-s2.0-77956018974 10.1159/000316179
Williamson L., Dalbeth N., Dockerty J. L., Gee B. C., Weatherall R., Wordsworth B. P., Extended report: nail disease in psoriatic arthritisclinically important, potentially treatable and often overlooked. Rheumatology 2004 43 6 790 794 2-s2.0-3042593371 10.1093/rheumatology/keh198 (Pubitemid 38807439)
de Berker D., Management of psoriatic nail disease. Seminars in Cutaneous Medicine and Surgery 2009 28 1 39 43 2-s2.0-63049083901 10.1016/j.sder.2008.12. 003
Wilson F. C., Icen M., Crowson C. S., McEvoy M. T., Gabriel S. E., Kremers H. M., Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis and Rheumatism 2009 61 2 233 239 2-s2.0-62549112548 10.1002/art.24172
Jiaravuthisan M. M., Sasseville D., Vender R. B., Murphy F., Muhn C. Y., Psoriasis of the nail: anatomy, pathology, clinicalpresentation, and a review of the literature on therapy. Journal of the American Academy of Dermatology 2007 57 1 1 27 2-s2.0-34250204897 10.1016/j.jaad.2005.07.073 (Pubitemid 46899261)
Langley R. G., Saurat J. H., Reich K., Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. Journal of the European Academy of Dermatology and Venereology 2012 26 373 381
Piérard G. E., Spores, sporodochia and fomites in onychomycosis. Dermatology 2006 213 2 169 172 2-s2.0-33747030600 10.1159/000093862 (Pubitemid 44215207)
Piérard G. E., Quatresooz P., Arrese J. E., Spotlight on nail histomycology. Dermatologic Clinics 2006 24 3 371 374 2-s2.0-33745192804 10.1016/j.det.2006.03.013
de Jong E. M., Seegers B. A., Gulinck M. K., Boezeman J. B., van de Kerkhof P. C., Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996 193 4 300 303 2-s2.0-0030445353
McGonagle D., Tan A. L., Benjamin M., The nail as a musculoskeletal appendageimplications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009 218 2 97 102 2-s2.0-59049086668 10.1159/000182250
Rich P., Guzzo C., Wang Y., Gordon K., Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a phase 3 trial. American Academy of Dermatology, Annual Meeting, 2008
Rich P., Langley R., Guzzo C., Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a pahse 3 trial (poster FP107). 17th Congress EADV, Paris, France, 2008
Rallis E., Kintzoglou S., Verros C., Ustekinumab for rapid treatment of nail psoriasis. Archives of Dermatology 2010 146 11 1315 1316 2-s2.0-78349273658 10.1001/archdermatol.2010.332
Patsatsi A., Kyriakou A., Sotiradis D., Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. Journal of Dermatological Treatment. In press
Rigopoulos D., Gregoriou S., Makris M., Ioannides D., Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 2011 223 325 329
Bianchi L., Bergamin A., de Felice C., Capriotti E., Chimenti S., Remission and time of resolution of nail psoriasis during infliximab therapy. Journal of the American Academy of Dermatology 2005 52 4 736 737 2-s2.0-17844386820 10.1016/j.jaad.2004.09.012 (Pubitemid 40585474)
Lawry M., Biological therapy and nail psoriasis. Dermatology and Therapy 2007 20 1 60 67 2-s2.0-34147106954 10.1111/j.1529-8019.2007.00112.x (Pubitemid 46568378)
van den Bosch F., Reece R., Behrens F., Clinically important nail psoriasis improvements are achieved with adalimumab (Humira): results from a large open-label prospective study (STEREO). Annals of Rheumatic Diseases 2007 66 supplement 2 421
Rich P., Griffiths C. E., Reich K., Nestle F. O., Scher R. K., Li S., Xu S., Hsu M. C., Guzzo C., Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology 2008 58 2 224 231 2-s2.0-38349097035 10.1016/j.jaad.2007.07.042
Rigopoulos D., Gregoriou S., Stratigos A., Larios G., Korfitis C., Papaioannou D., Antoniou C., Ioannides D., Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. British Journal of Dermatology 2008 159 2 453 456 2-s2.0-47549099185 10.1111/j.1365-2133.2008.08686.x (Pubitemid 352009870)
Kragballe K., Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails. Current Problems in Dermatology 2009 38 160 171 2-s2.0-70350501147 10.1159/000232309
Reich K., Approach to managing patients with nail psoriasis. Journal of the European Academy of Dermatology and Venereology 2009 23 supplement 1 15 21 2-s2.0-69049113992 10.1111/j.1468-3083.2009.03364.x
Langley R. G., Daudén E., Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010 221 supplement 1 29 42 2-s2.0-77956018974 10.1159/000316179
Rigopoulos D., Gregoriou S., Lazaridou E., Belyayeva E., Apalla Z., Makris M., Katsambas A., Ioannides D., Treatment of nail psoriasis with adalimumab: an open label unblinded study. Journal of the European Academy of Dermatology and Venereology 2010 24 5 530 534 2-s2.0-77950851217 10.1111/j.1468-3083.2009.03453.x
de Berker D., Management of nail psoriasis. Clinical and Experimental Dermatology 2000 25 5 357 362 2-s2.0-0033778442 10.1046/j.1365-2230.2000.00663.x
Baran R. L., A nail psoriasis severity index. British Journal of Dermatology 2004 150 3 568 569 2-s2.0-1842506631 10.1046/j.1365-2133.2003.05725. x (Pubitemid 38446315)
Cannavò S. P., Guarneri F., Vaccaro M., Borgia F., Guarneri B., Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003 206 2 153 156 2-s2.0-0037275220 10.1159/000068469 (Pubitemid 36205284)
Ortonne J. P., Baran R., Corvest M., Schmitt C., Voisard J. J., Taieb C., Development and validation of nail psoriasis quality of life scale (NPQ10). Journal of the European Academy of Dermatology and Venereology 2010 24 1 22 27 2-s2.0-71949111509 10.1111/j.1468-3083.2009.03344.x
Nikkels-Tassoudji N., Pierard-Franchimont C., De Doncker P., Pierard G. E., Optical profilometry of nail dystrophies. Dermatology 1995 190 4 301 304 2-s2.0-0029033488
Piérard G. E., Piérard-Franchimont C., Dynamics of psoriatic trachyonychia during low-dose cyclosporin A treatment: a pilot study on onychochronobiology using optical profilometry. Dermatology 1996 192 2 116 119 2-s2.0-0030053728 (Pubitemid 26072441)
Piérard-Franchimont C., Piérard G. E., Surface image analysis of nail alterations in juvenile pityriasis rubra pilaris. Skin Research and Technology 1998 4 1 34 36 2-s2.0-0031929553 10.1111/j.1600-0846.1998. tb00083.x (Pubitemid 28105266)
Piérard G. E., Caucanas M., Piérard-Franchimont C., Berardesca E., Wilhelm K. P., Maibach H. I., Nail surface topography and onychochronobiology. Noninvasive diagnostic techniques in clinical dermatology 2012 Berlin, Germany Springer
Aydin S. Z., Ash Z., Del Galdo F., Marzo-Ortega H., Wakefield R. J., Emery P., McGonagle D., Optical coherence tomography: a new tool to assess nail disease in psoriasis? Dermatology 2011 222 311 313 2-s2.0-79960695302 10.1159/000329434
Stenn K. S., Paus R., Controls of hair follicle cycling. Physiological Reviews 2001 81 1 449 494 2-s2.0-0035134022 (Pubitemid 32096181)
Piérard-Franchimont C., Piérard G. E., Teloptosis, a turning point in hair shedding biorhythms. Dermatology 2001 203 2 115 117 2-s2.0-0035742449 10.1159/000051723 (Pubitemid 34701568)
Courtois M., Loussouarn G., Hourseau C., Grollier J. F., Hair cycle and alopecia. Skin Pharmacology 1994 7 1-2 84 89 2-s2.0-0028258541 (Pubitemid 24086198)
Piérard-Franchimont C., Petit L., Loussouarn G., Saint-Léger D., Piérard G. E., The hair eclipse phenomenon: sharpening the focus on the hair cycle chronobiology. International Journal of Cosmetic Science 2003 25 6 295 299 2-s2.0-0348162508 10.1111/j.1467-2494.2003. 00198.x (Pubitemid 38005441)
Piérard G. E., Piérard-Franchimont C., Marks R., Elsner P., The EEMCO Group, EEMCO guidance for the assessment of hair shedding and alopecia. Skin Pharmacology and Physiology 2004 17 2 98 110 2-s2.0-10744230966 10.1159/000076020 (Pubitemid 38250517)
Kim K. S., Shin M. K., Ahn J. J., Haw C. R., Park H. K., A comparative study of hair shafts in scalp psoriasis and seborrheic dermatitis using atomic force microscopy. Skin Research and Technology. In press
Shin M. K., Kim K. S., Ahn J. J., Kim N. I., Park H. K., Haw C. R., Investigation of the hair of patients with scalp psoriasis using atomic force microscopy. Clinical and Experimental Dermatology 2012 37 156 163
Di Cesare A., Fargnoli M. C., Peris K., Rapid response of scalp psoriasis to ustekinumab. European Journal of Dermatology 2011 21 993 994
Chan C. S., Van Voorhees A. S., Lebwohl M. G., Korman N. J., Young M., Bebo B. F., Kalb R. E., Hsu S., Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2009 60 6 962 971 2-s2.0-67349249703 10.1016/j.jaad.2008. 11.890
Bagel J., Lynde C., Tyring S., Kricorian G., Shi Y., Klekotka P., Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. Journal of the American Academy of Dermatology 2012 67 86 92
Leonardi C. L., Kimball A. B., Papp K. A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L. T., Gordon K. B., Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet 2008 371 9625 1665 1674 2-s2.0-43449111187 10.1016/S0140-6736(08) 60725-4 (Pubitemid 351671883)
Ruiz Salas V., Puig L., Alomar A., Ustekinumab in clinical practice: response depends on dose and previous treatment. Journal of the European Academy of Dermatology and Venereology 2012 26 506 513
